AI Article Synopsis
- - Structure-based drug design (SBDD) utilizes crystallographic data to enhance the effectiveness and selectivity of drugs by focusing on how ligands interact with their target proteins.
- - The authors suggest incorporating normalized B-factors, which indicate protein dynamics, into the drug optimization process for a more comprehensive understanding of ligand binding.
- - A case study on crizotinib and lorlatinib demonstrated that ligand binding not only stabilizes the protein directly around it but also influences more distant regions, highlighting new opportunities for improving SBDD methods.
Article Abstract
Structure-based drug design (SBDD) is commonly leveraged in rational drug design. Usually, ligand and binding site atomic coordinates from crystallographic data are exploited to optimize potency and selectivity. In addition to traditional, static views of proteins and ligands, we propose using normalized B-factors to study protein dynamics as a part of the drug optimization process. A retrospective case study of crizotinib and lorlatinib bound to both c-ros oncogene 1 kinase (ROS1) and anaplastic lymphoma kinase (ALK) L1196M related normalized B-factors to differences in binding affinity. This analysis showed that ligand binding can have protein-stabilizing effects that start near the ligand but propagate through nearby residues and structural waters to more distal motifs. The potential opportunities for analyzing normalized B-factors in SBDD are also discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142050 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.8b00147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!